On the stock market since 2014, it operates in the world of health and science. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
No real growth (-1% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The company sells $1.9M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $40.6M against $1.9M in annual sales.
The stock sits at $0.27. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, ARGS sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ARGS is a small company that closed last year at a loss. The road back to profit runs through spending discipline.